Correction: Screening potential anti-osteoarthritis compounds using molecular docking based on MAPK and NFκB pathways and validating their anti-osteoarthritis effect
Tian-Wang Zhu, Yu Zheng, Rui-Xin Li
Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsInflammatory mediators and NSAID effects · Osteoarthritis Treatment and Mechanisms · Pharmacological Effects of Medicinal Plants
The caption for Fig 1 is incorrect. Please see the correct Fig 1 caption here.
Fig 1. The roles of the MAPK and NFκB pathways in the onset and progression of osteoarthritis.
The following information should have been the last paragraph of Introduction section: Molecular docking is a powerful computational technique used to simulate the interaction between a compound and a protein to evaluate their binding potential. As a strong competitor to high-throughput omics, this technique has been widely used in drug discovery [10]. However, to our knowledge, no studies focused on screening anti-osteoarthritis compounds using molecular docking. This study aimed to screen potential anti-osteoarthritis compounds by docking with core human proteins in the MAPK and NFκB pathways, analyze their drug-likeness, pharmacokinetics, bioactivity, and toxicity, and test their cytotoxicity and anti-osteoarthritis effect on mouse chondrocytes.
The reference list from the paper itself. Each links out to its DOI / PubMed record.